Search

Search Results for "Regeneron Pharmaceuticals"

Dosing Considerations with 8 mg Aflibercept thumbnail

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

High-Dose Aflibercept: Promising Results thumbnail

High-Dose Aflibercept: Promising Results

Lloyd Clark, MD, FASRS

High-Dose Aflibercept: 48-Week Data thumbnail

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Real-World Data for 8 mg Aflibercept thumbnail

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

A Closer Look at 8 mg Aflibercept thumbnail

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Anti-VEGF for ROP: Efficacy and Safety Outcomes thumbnail

Anti-VEGF for ROP: Efficacy and Safety Outcomes

Andreas Stahl, MD

96-Week Safety Data Revealed for 8 mg Aflibercept thumbnail

96-Week Safety Data Revealed for 8 mg Aflibercept

Christina Y. Weng, MD, MBA

Treatment Burden: EYP-1901 Versus Aflibercept thumbnail

Treatment Burden: EYP-1901 Versus Aflibercept

Avni P. Finn, MD, MBA

Exploring DME Outcomes Based on Baseline Vision thumbnail

Exploring DME Outcomes Based on Baseline Vision

Diana V. Do, MD

Extension Data for High-Dose Aflibercept thumbnail

Extension Data for High-Dose Aflibercept

Diana Do, MD

Outcomes with 8 mg Aflibercept; Does Prior DME Treatment Matter? thumbnail

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Additional Considerations for Treating ROP thumbnail

Additional Considerations for Treating ROP

Faruk Orge, MD; Darius Moshfeghi, MD

Decision Factors in managing patients with ROP thumbnail

Decision Factors in managing patients with ROP

Faruk Orge, MD; and Darius Moshfeghi, MD

ICROP Classification and ROP Treatment Guidelines thumbnail

ICROP Classification and ROP Treatment Guidelines

Faruk Orge, MD; and Darius Moshfeghi, MD

Protocol AC: Step Therapy in DME thumbnail

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

A Treatment Paradigm for Wet AMD thumbnail

A Treatment Paradigm for Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague thumbnail

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Phase 3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of Wet
AMD thumbnail

Phase 3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Phase 2/3 Clinical Trial Data for EYLEA HD<sup>®</sup> (aflibercept) Injection 8 mg for the Treatment of DME thumbnail

Phase 2/3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of DME

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data

David Brown, MD and Robert Mittra, MD

View More